CD8

[Nature] Scientists demonstrated that a trispecific antibody to HER2, CD3 and CD28 stimulated regression of breast cancers in a humanized mouse model through a mechanism involving CD4-dependent inhibition of tumor cell cycle progression.

[Molecular Therapy-Oncolytics] The authors reported a new strategy of blocking the CD7 antigen on the T cell surface with a recombinant anti-CD7 antibody to obtain a sufficient amount of CD7-targeting CAR-T cells for T cell acute lymphoblastic leukemia treatment.

[Hepatology] Scientists analyzed the immune landscapes of hypoxia-low and -high tumor regions using cytometry by time-of-flight, immunohistochemistry and transcriptomic analyses.

[iScience] Investigators evaluated the immune properties of the HLA-A2 restricted CD8+ T cell epitopes containing mutations from B.1.1.7.

[Nature Immunology] Researchers showed that the transcription factor Tcf1 was required in resting central memory CD8+ T cells to generate secondary effector CD8+ T cells and to clear pathogens during recall responses.

[International Immunopharmacology] Scientists found that C-C motif chemokine ligand 2 (CCL2) recruits monocytes to and decrease CD8+ T cell infiltration in pancreatic tumors.